Amlitelimab

艾莫特利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAmlitelimab
Drug Alias NameKY-1005SAR-445229
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 4 inhibitors
TargetsTumor necrosis factor ligand superfamily member 4
Therapy Area/IndicationsImmune System DiseasesHidradenitisAlopecia Areata +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKymab LtdSanofi
China Registration ClassN/A

Develop Information

Active CompaniesScleroderma Research Foundation IncKymab LtdSanofi +[7] 
Inactive CompaniesN/A
Active IndicationsAlopecia AreataEczemaScleroderma, Systemic +[7] 
Inactive IndicationsImmune System DiseasesHidradenitis

Other Information

ATC CodeN/A
Related LinksDrugBank